Dolutegravir-based regimens in the post-partum period

Lancet HIV. 2023 Jun;10(6):e352-e353. doi: 10.1016/S2352-3018(23)00086-3. Epub 2023 May 8.

Author

Thokozile Malaba¹

Affiliation

¹ Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town 7925, South Africa. Electronic address: thoko.malaba@uct.ac.za.

PMID: 37167995
DOI: 10.1016/S2352-3018(23)00086-3

No abstract available

Publication types

Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
Female
HIV Infections* / drug therapy
Heterocyclic Compounds, 3-Ring / therapeutic use
Humans
Oxazines / therapeutic use
Postpartum Period

Substances

dolutegravir
Oxazines
Anti-HIV Agents
Heterocyclic Compounds, 3-Ring